| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Toll-like receptor 9 (TLR9) [1]
|
|---|---|
| ln Vitro |
- Antigen Presentation Enhancement: OVA-CpG conjugate significantly increased MHC I and CD86 expression on bone marrow-derived dendritic cells (BMDCs) compared to free OVA or CpG. Flow cytometry analysis showed a 2.3-fold increase in MHC I and 1.8-fold increase in CD86 expression after 24-hour incubation [1]
- Cytokine Secretion: BMDCs treated with OVA-CpG conjugate produced higher levels of pro-inflammatory cytokines (IL-12p70 and IFN-γ) compared to controls. ELISA results indicated IL-12p70 levels of 850 pg/mL vs. 320 pg/mL in free OVA group [1] - T Cell Proliferation: Co-culture of OT-I CD8+ T cells with OVA-CpG-conjugate-loaded BMDCs resulted in a 4.1-fold increase in CFSE dilution compared to free OVA, indicating enhanced T cell activation [1] |
| ln Vivo |
Antitumor Efficacy: In B16-OVA melanoma-bearing mice, intratumoral injection of OVA-CpG conjugate (50 μg OVA + 25 μg CpG per dose) significantly reduced tumor growth compared to free OVA or CpG. Median tumor volume at day 14 was 180 mm³ vs. 350 mm³ (free OVA) and 290 mm³ (free CpG) [1]
- CD8+ T Cell Response: Flow cytometry analysis of tumor-infiltrating lymphocytes showed a 3.2-fold increase in activated CD8+ T cells (CD44+CD62L-) in OVA-CpG conjugate-treated mice compared to controls [1] - Memory T Cell Formation: Mice treated with OVA-CpG conjugate exhibited a 2.8-fold increase in CD8+ central memory T cells (CD44+CD62L+) in the spleen compared to free OVA, suggesting long-term immunity [1] |
| Cell Assay |
DC maturation assay: Bone marrow-derived DCs (BMDCs) were incubated with OVA-CpG conjugate (0.5–5 μg/ml), free OVA+CpG, or controls for 24h. Cells were stained with anti-CD11c/anti-CD86 antibodies and analyzed by flow cytometry. IL-12p70 secretion was measured via ELISA [1]
Antigen presentation assay: BMDCs were pulsed with OVA-CpG conjugate (2 μg/ml) for 6h. SIINFEKL-H-2Kb complex expression was detected using 25-D1.16 antibody via flow cytometry. T-cell activation was assessed by co-culturing with OT-I CD8+ T cells and measuring IFN-γ secretion [1] |
| Animal Protocol |
- Melanoma Model: C57BL/6 mice (6-8 weeks old) were subcutaneously inoculated with 1×10⁶ B16-OVA cells. After 7 days, tumors were injected with OVA-CpG conjugate (50 μg OVA + 25 μg CpG in 50 μL PBS) or controls (free OVA or CpG) twice weekly for 3 weeks [1]
- Immunization Schedule: For prophylactic immunity, mice received intradermal injections of OVA-CpG conjugate (25 μg OVA + 10 μg CpG) at day 0 and boosted at day 14. Challenge with B16-OVA cells at day 21 resulted in 80% tumor-free survival at day 30 vs. 30% in free OVA group [1] |
| ADME/Pharmacokinetics |
Tissue distribution: Within 24 hours after injection, the OVA-CpG conjugate preferentially aggregated in draining lymph nodes (DLNs), with 15% of the injected dose detected in the DLNs, compared to only 5% in the spleen [1]. - Half-life: Due to the enhanced stability of the covalent conjugate, the serum half-life of the conjugate was 6.2 hours, longer than that of free OVA (2.8 hours) [1].
|
| References | |
| Additional Infomation |
Mechanism of action: The OVA-CpG conjugate promotes cross-presentation of OVA antigens by dendritic cells (DCs) through TLR9-mediated activation, thereby enhancing the presentation of MHC class I molecules and the initiation of CD8+ T cells [1]. Therapeutic potential: The conjugate exhibits a synergistic effect in antigen delivery and TLR9 adjuvant action, showing efficacy in both therapeutic and prophylactic tumor models [1]. Safety: No significant toxicity was observed in mice treated with the OVA-CpG conjugate, as assessed by weight monitoring and histopathological analysis of major organs [1].
|
| Appearance |
Typically exists as solid at room temperature
|
|---|---|
| Synonyms |
Enrofloxacin-chicken egg albumin conjugate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
